Real-World study checks Tivozanib's performance in kidney cancer

NCT ID NCT07354282

Completed Knowledge-focused Sponsor: Spanish Oncology Genito-Urinary Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked back at the medical records of 200 patients with advanced clear cell kidney cancer who received Tivozanib as their first treatment. The goal was to see how long patients went without their cancer getting worse and how long they lived overall. The study focused on patients considered to have a favorable outlook based on a standard risk score.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tivozanib
What this could lead to: If results are positive, this could confirm that Tivozanib is a good first-line option for certain patients with advanced kidney cancer.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It only looks back at past data and cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CANCER METASTATIC

Contacts and locations

Locations

Fundacion Jimenez Diaz

Madrid, Madrid, Spain
Hospital Gregorio Marañon

Madrid, Madrid, Spain
Hospital Lucus Augusti

Lugo, Galicia, Spain
Hospital Parc Tauli

Sabadell, Catalonia, Spain
Hospital Puerta de Hierro

Majadahonda, Madrid, Spain
Hospital Reina Sofia

Córdoba, Andalusia, Spain
Hospital Severo Ochoa

Leganés, Madrid, Spain
Hospital Vall de Hebron

Barcelona, Catalonia, Spain
Hospital Virgen de la Victoria

Málaga, Andalusia, Spain
Hospital Virgen del Rocio

Seville, Andalusia, Spain
Hospital de Burgos

Burgos, Castille and León, Spain
Hospital de Leon

León, Castille and León, Spain
Institut Català d'Oncologia (ICO) de L'Hospitalet de Llobregat

L'Hospitalet de Llobregat, Catalonia, Spain
Instituto Valenciano de Oncologia (IVO)

Valencia, Valencia, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.